Your session is about to expire
← Back to Search
Proton Beam Therapy
Proton Therapy for Kidney Cancer
Phase < 1
Recruiting
Led By Christine Hill-Kayser, MD
Research Sponsored by Children's Hospital of Philadelphia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
The patient is a candidate for external beam radiotherapy based on standard of care for treatment of Wilms tumor or CCSK
Diagnosis of Wilms tumor or clear cell sarcoma of the kidney requiring radiation therapy as standard of care, including favorable histology (FH), stage III disease, focal or diffuse anaplasia, or CCSK
Must not have
Chemotherapy administered for diagnosis of Wilms tumor or CCSK
Prior radiotherapy to the region of the study cancer
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 90 days
Awards & highlights
Summary
This trial is testing proton therapy to treat renal tumors in the flank region to see if it is safe.
Who is the study for?
This trial is for patients under 30 years old with renal tumors, specifically Wilms tumor or clear cell sarcoma of the kidney (CCSK), who need radiation therapy as part of their standard care. It's not open to those who are pregnant, breastfeeding, have had previous radiotherapy in the cancer area, or chemotherapy for these diagnoses.Check my eligibility
What is being tested?
The study is testing how safe and tolerable proton beam radiation using pencil beam scanning is for treating renal tumors. This pilot study focuses on acute toxicity experienced by patients receiving this type of flank irradiation.See study design
What are the potential side effects?
While specific side effects aren't listed here, acute toxicity generally refers to immediate reactions from treatment such as skin irritation, fatigue, nausea or other organ-specific issues depending on the radiation target area.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am eligible for a type of radiation therapy for my Wilms tumor or CCSK.
Select...
I have been diagnosed with a specific kidney cancer that needs radiation.
Select...
I am under 30 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have received chemotherapy for Wilms tumor or CCSK.
Select...
I have had radiation therapy on the cancer area being studied.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 90 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~90 days
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Occurrence of any non-hematologic toxicity that occurs within 90 days following the start of proton therapy assessed with with NCI Common toxicity criteria (CTC Version 4.0) grades].
Trial Design
1Treatment groups
Experimental Treatment
Group I: Renal tumorsExperimental Treatment1 Intervention
Any patient with Wilms tumor or clear cell sarcoma of the kidney who would require radiation therapy as standard of care. Patients may receive an investigation drug for Wilms or CCSK given concurrently or within the first four weeks of the first fraction of proton therapy administration.
Find a Location
Who is running the clinical trial?
Children's Hospital of PhiladelphiaLead Sponsor
712 Previous Clinical Trials
8,589,989 Total Patients Enrolled
Christine Hill-Kayser, MDPrincipal InvestigatorChildren's Hospital of Philadelphia
2 Previous Clinical Trials
55 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am eligible for a type of radiation therapy for my Wilms tumor or CCSK.I have received chemotherapy for Wilms tumor or CCSK.I have been diagnosed with a specific kidney cancer that needs radiation.I am under 30 years old.I have had radiation therapy on the cancer area being studied.
Research Study Groups:
This trial has the following groups:- Group 1: Renal tumors
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger